Recent Comments

Comment RSS

TNF Blockers News and Research RSS Feed - TNF Blockers News and Research

TNF therapy does not raise cancer risk in RA patients; overall cancer risk comparable to those not taking immunosuppressive drugs

29. October 2009 01:00
A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy. [More]

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

28. October 2009 08:22
According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study. [More]

New data from efficacy study of CIMZIA in Crohn's disease patients presented

27. October 2009 05:04
New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years. [More]

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

20. October 2009 05:35
Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA). [More]

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

19. October 2009 23:55
UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks. [More]

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

19. October 2009 09:41
New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting. [More]

Cimzia approved for treating adult patients with rheumatoid arthritis

1. September 2009 06:41
UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). [More]

Expert available on recent FDA analysis of TNF blockers

9. August 2009 20:03
Lloyd J. Old, M.D., is Director of the Ludwig Institute for Cancer Research (LICR) New York Branch. He is also Director of the Cancer Research Institute (CRI) Scientific Advisory Council, Director of the CRI/LICR Cancer Vaccine Collaborative, and Director of the CRI Cancer Vaccine Consortium. He has been a Member of the National Academy of Sciences since 1978. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , ,

Golimumab shows promise for rheumatoid arthritis

28. June 2009 21:37
Golimumab, a new tumour necrosis factor-α (TNF-α) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-α inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-α inhibitors, finds an Article published Online first and in this week's edition of The Lancet. [More]

Posted in: Drug Trial News

Tags: , , , , ,

Roche files MabThera as a first-line biologic treatment for rheumatoid arthritis in Europe

28. June 2009 21:01
Roche has announced that it has submitted a combined filing to the European health authorities (the European Medicines Agency) for three new indications to extend the label for MabThera to use as a first-line biologic therapy for patients with rheumatoid arthritis (RA). [More]

Posted in: Pharmaceutical News

Tags: , , ,

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

20. May 2009 02:16
Genentech, Inc. and Biogen Idec today announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL). [More]

Adult stem cells from bone marrow can deliver cancer-killing proteins to tumors

19. May 2009 16:50
Researchers in London have demonstrated the ability of adult stem cells from bone marrow (mesenchymal stem cells, or MSCs) to deliver a cancer-killing protein to tumors. [More]

Posted in: Medical Research News

Tags: , , , ,

Cimzia approved in U.S. for rheumatoid arthritis

13. May 2009 23:11
UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). [More]

Senior men more likely than women to die after pneumonia

29. April 2009 23:49
Differing biological response to infection between men and women may explain higher death rates among older men who are hospitalized with community-acquired pneumonia (CAP). [More]

Posted in: Medical Research News

Tags: , , , , , , , , ,

Overexpression of PEA-15 protein shrinks breast cancer tumors

20. April 2009 23:15
Overexpression of PEA-15, which binds and drags an oncoprotein out of the cell nucleus where it fuels cancer growth, steeply reduced breast cancer tumors in a preclinical experiment, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.